These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 16698763)

  • 21. Silybin counteracts lipid excess and oxidative stress in cultured steatotic hepatic cells.
    Vecchione G; Grasselli E; Voci A; Baldini F; Grattagliano I; Wang DQ; Portincasa P; Vergani L
    World J Gastroenterol; 2016 Jul; 22(26):6016-26. PubMed ID: 27468193
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differences in the disposition of silymarin between patients with nonalcoholic fatty liver disease and chronic hepatitis C.
    Schrieber SJ; Hawke RL; Wen Z; Smith PC; Reddy KR; Wahed AS; Belle SH; Afdhal NH; Navarro VJ; Meyers CM; Doo E; Fried MW
    Drug Metab Dispos; 2011 Dec; 39(12):2182-90. PubMed ID: 21865319
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Therapeutic effect of metformin and vitamin E versus prescriptive diet in obese adolescents with fatty liver.
    Akcam M; Boyaci A; Pirgon O; Kaya S; Uysal S; Dundar BN
    Int J Vitam Nutr Res; 2011 Nov; 81(6):398-406. PubMed ID: 22673924
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of spironolactone and vitamin E on serum metabolic parameters and insulin resistance in patients with nonalcoholic fatty liver disease.
    Polyzos SA; Kountouras J; Zafeiriadou E; Patsiaoura K; Katsiki E; Deretzi G; Zavos C; Tsarouchas G; Rakitzi P; Slavakis A
    J Renin Angiotensin Aldosterone Syst; 2011 Dec; 12(4):498-503. PubMed ID: 21436212
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Study of clinical efficiency of essential phospholipids and silymarin combination in nonalcoholic and alcoholic steatohepatitis].
    Iakimchuk GN; Gendrikson LN
    Eksp Klin Gastroenterol; 2011; (7):64-9. PubMed ID: 22364002
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of nonalcoholic steatohepatitis: antioxidants or insulin sensitizers?
    Adams LA; Angulo P
    Clin Gastroenterol Hepatol; 2004 Dec; 2(12):1059-60. PubMed ID: 15625648
    [No Abstract]   [Full Text] [Related]  

  • 27. Investigation of the effects of Chlorella vulgaris supplementation in patients with non-alcoholic fatty liver disease: a randomized clinical trial.
    Panahi Y; Ghamarchehreh ME; Beiraghdar F; Zare R; Jalalian HR; Sahebkar A
    Hepatogastroenterology; 2012 Oct; 59(119):2099-2103. PubMed ID: 23234816
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nonalcoholic fatty liver disease: current issues and novel treatment approaches.
    Lomonaco R; Sunny NE; Bril F; Cusi K
    Drugs; 2013 Jan; 73(1):1-14. PubMed ID: 23329465
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment with silybin-vitamin E-phospholipid complex in patients with hepatitis C infection.
    Falasca K; Ucciferri C; Mancino P; Vitacolonna E; De Tullio D; Pizzigallo E; Conti P; Vecchiet J
    J Med Virol; 2008 Nov; 80(11):1900-6. PubMed ID: 18814247
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Assessment of effectiveness of livolin forte in the treatment of patient with steatohepatitis].
    Svintsitskiĭ AS; Revenok EN; Solov'eva GA; Tkachuk AI
    Lik Sprava; 2003; (2):76-80. PubMed ID: 12774483
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Review article: Drug therapy for non-alcoholic fatty liver disease.
    Comar KM; Sterling RK
    Aliment Pharmacol Ther; 2006 Jan; 23(2):207-15. PubMed ID: 16393299
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Silymarin in Combination with Vitamin C, Vitamin E, Coenzyme Q10 and Selenomethionine to Improve Liver Enzymes and Blood Lipid Profile in NAFLD Patients.
    Curcio A; Romano A; Cuozzo S; Nicola AD; Grassi O; Schiaroli D; Nocera GF; Pironti M
    Medicina (Kaunas); 2020 Oct; 56(10):. PubMed ID: 33080906
    [No Abstract]   [Full Text] [Related]  

  • 33. Milk thistle to treat non-alcoholic fatty liver disease: dream or reality?
    Abenavoli L; Bellentani S
    Expert Rev Gastroenterol Hepatol; 2013 Nov; 7(8):677-9. PubMed ID: 24134155
    [No Abstract]   [Full Text] [Related]  

  • 34. Genistein improves liver function and attenuates non-alcoholic fatty liver disease in a rat model of insulin resistance.
    Mohamed Salih S; Nallasamy P; Muniyandi P; Periyasami V; Carani Venkatraman A
    J Diabetes; 2009 Dec; 1(4):278-87. PubMed ID: 20923528
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Metformin, vitamin E, and diet for patients with nonalcoholic fatty liver disease.
    Kadayifci A; Merriman RB
    Am J Gastroenterol; 2006 Jun; 101(6):1396; author reply 1396-7. PubMed ID: 16771968
    [No Abstract]   [Full Text] [Related]  

  • 36. Medical therapy for nonalcoholic fatty liver disease in children and adolescents.
    Andrews DB; Lavine JE
    Expert Rev Gastroenterol Hepatol; 2012 Feb; 6(1):1-3. PubMed ID: 22149573
    [No Abstract]   [Full Text] [Related]  

  • 37. Relationship between adipose tissue insulin resistance and liver histology in nonalcoholic steatohepatitis: a pioglitazone versus vitamin E versus placebo for the treatment of nondiabetic patients with nonalcoholic steatohepatitis trial follow-up study.
    Bell LN; Wang J; Muralidharan S; Chalasani S; Fullenkamp AM; Wilson LA; Sanyal AJ; Kowdley KV; Neuschwander-Tetri BA; Brunt EM; McCullough AJ; Bass NM; Diehl AM; Unalp-Arida A; Chalasani N;
    Hepatology; 2012 Oct; 56(4):1311-8. PubMed ID: 22532269
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hepatoprotective and antiviral functions of silymarin components in hepatitis C virus infection.
    Polyak SJ; Ferenci P; Pawlotsky JM
    Hepatology; 2013 Mar; 57(3):1262-71. PubMed ID: 23213025
    [No Abstract]   [Full Text] [Related]  

  • 39. Silibinin ameliorates steatosis and insulin resistance during non-alcoholic fatty liver disease development partly through targeting IRS-1/PI3K/Akt pathway.
    Zhang Y; Hai J; Cao M; Zhang Y; Pei S; Wang J; Zhang Q
    Int Immunopharmacol; 2013 Nov; 17(3):714-20. PubMed ID: 24036369
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nonalcoholic fatty liver disease: Targeted therapy in children--what is the right way?
    Alisi A; Nobili V
    Nat Rev Gastroenterol Hepatol; 2011 Jul; 8(8):425-6. PubMed ID: 21750513
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.